LGD-2226 powder is an selective androgen receptor modulator, which is being developed for treatment of muscle wasting and osteoporosis. LGD-2226 isan orally active, potent and selective agonist for androgen receptors which was shown to have anabolic effects in both muscle and bone tissue, but with considerably less effects on prostate weight and lutenizing hormone levels than testosterone .LGD-2226 powder is also an orally activenonsteroidal SARM that has been shown to increase muscle mass, strengthen bones, and improve sexual function in male rats without significantly affecting prostate size.
02 LGD-2226 powder (328947-93-9) video
03 LGD-2226 powder (328947-93-9) Base Information
|Molecular Weight||392.2246 g/mol|
|Appearance||White or off white Crystalline|
|Half Life||8-14 hours|
|Solubility||Soluble in DMSO, not in water|
|Storage Condition||Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).|
|Application||LGD-2226 is an orally active potent and selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis. Show to have an anabolic effect on muscle and bone tissue.|
04 LGD-2226 powder Description
LGD-2226 powder is an investigational drug developed for the treatment of osteoporosis and muscle wasting. The drug is a selective androgen receptor modulator and is designed to provide an alternative to the use of steroids for bodybuilders too. LGD2226 is fully active in cell-based models ofbone and muscle, exhibits anabolic activity on muscle and bone with reduced impact on prostate growth in rodent models; LGD2226 is also efficacious in a sex-behavior model in male rats measuring mounts, intromissions, ejaculations, and copulation efficiency.
Safety is at the forefront of the development of LGD-2226. It does not have any safety issues and does not come along with any serious side effects.At the same time, however, it’s still able to provide massive bodybuilding and fitness benefits that rival those from taking anabolic steroidssuch as testosterone. This makes LGD2226 a viable alternative to anabolic steroids. It’s a performance enhancing drug that you can take withoutany potential for harm or damage. LGD2226 is also relatively mild. Even though it has powerful benefits, you won’t be pumping your body fullof outside substances.You can take a relatively small amount of the SARM over a relatively short period of time and experience amazing results without any negative effects.
05 LGD-2226 powder (328947-93-9) History
Clinical trials on LGD-2226 powder and its effects are ongoing but initial tests have shown that the chemical has some anabolic effects on bone and muscle tissue. The biggest plus though for LGD-2226 is the fact that trials so far have shown it has relatively fewer effects on the prostate and luteinizing hormone levels compared to steroids and other SARMs.
06 2226 (328947-93-9) Mechanism Of Action
LGD-2226 is a powerful and orally active SARM that works just like any other. This SARM targets muscle and bone cells. It helps to trigger androgenic action in cases where the testosterone levels in the body are not enough to do so. The body produces testosterone in a regulated manner and in some cases, the hormone may not be enough to trigger the required androgenic action to keep the body’s stamina up for workouts.
In addition to this, in worse case scenarios, testosterone produced in the body may be so little, leading to muscle wasting. LGD-2226 can be used as a solution for all these issues. Its selective action will trigger androgenic activities in muscle cells while ensuring that normal production of testosterone remains intact. For bodybuilders, this can help improve workout intensity, leading to better results.
07 LGD-2226 (328947-93-9) Application
LGD-2226 is an investigational selective androgen receptor modulator (SARM), which is being developed for treatment of muscle wasting and osteoporosis.
LGD-2226 is an orally active, potent and selective agonist for androgen receptors which was shown to have anabolic effects in both muscle and bone tissue, but with considerably less effects on prostate weight and lutenizing hormone levels than testosterone. Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to anabolic steroids but with significantly less side effects.
08 LGD-2226 (328947-93-9) More research
LGD2226 is a nonsteroidal, nonaromatizable, highly selective ligand for the AR, exhibiting virtually no affinity for the other intracellular receptors. It is also an orally administered drug and should be taken using water or juice. We determined that AR bound to LGD2226 exhibits a uniquepattern of protein-protein interactions compared with testosterone, fluoxymesterone (an orally available steroidal androgen), and other steroids, suggesting that LGD2226 alters the conformation of the ligand-binding domain. We demonstrated that LGD2226 is fully active in cell-based models of bone and muscle. LGD2226 exhibited anabolic activity on muscle and bone with reduced impact on prostate growth in rodent models. Biomechanical testing of bones from animals treated with LGD2226 showedstrong enhancement of bone strength above sham levels. These results with an orally available, nonaromatizable androgen demonstrate the important role of the AR and androgens in mediating a number of beneficial effects in bone, muscle, and sexual function independent from the conversion of androgens into estrogenic ligands. Taken together, these results suggest that orally active, nonsteroidal selective androgen receptor modulators may be useful therapeutics for enhancing muscle, bone, and sexualfunction.
09 LGD-2226 (328947-93-9) Document Download
10 LGD-2226 (328947-93-9) Reference
1: Hong MH, Sun H, Jin CH, Chapman M, Hu J, Chang W, Burnett K, Rosen J,Negro-Vilar A, Miner JN. Cell-specific activation of the human skeletal alpha-actin by androgens. Endocrinology. 2008 Mar;149(3):1103-12. Epub 2007 Dec 6. PubMed PMID: 18063690.
2: Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Commun Mass Spectrom. 2007;21(21):3477-86. PubMed PMID: 17985352.
3: van Oeveren A, Motamedi M, Mani NS, Marschke KB, López FJ, Schrader WT, Negro-Vilar A, Zhi L. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6. PubMed PMID: 17034117.
4: Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, MarschkeKB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally active selective androgen receptor modulator is efficacious onbone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. PubMed PMID: 17023534.
- 01. Overview
- 02. LGD-2226 powder (328947-93-9) video
- 03. LGD-2226 powder (328947-93-9) Base Information
- 04. LGD-2226 powder Description
- 05. LGD-2226 powder (328947-93-9) History
- 06. 2226 (328947-93-9) Mechanism Of Action
- 07. LGD-2226 (328947-93-9) Application
- 08. LGD-2226 (328947-93-9) More research
- 09. LGD-2226 (328947-93-9) Document Download
- 10. LGD-2226 (328947-93-9) Reference